Another study was performed in which simvastatin and mevastatin effectively revert doxorubicin resistance in human malignant mesothelioma through inactivation of the ABC transporter P-gp via nitric oxide (NO)-dependent nitration in the tyrosine residue of P-gp, responsible for the efflux of doxorubicin [279]. Here, PGP is linked to malignant mesothelioma.